Neumora Therapeutics counts several prominent corporate entities, venture capital firms, and institutional investors among its primary stakeholders. Biotechnology pioneer Amgen holds a significant corporate equity stake following strategic research and development collaborations, while ARCH Venture Partners stands out as a leading venture capital backer with substantial board and equity representation. Additional institutional holdings are managed by specialized healthcare funds, public equity advisors such as Invus, and various alternative asset management firms that participated in the company's funding rounds prior to and following its public market debut.